Impact of bisphosphonate treatment on bone mineral density after kidney transplant.

世界移植杂志 Pub Date : 2024-09-18 DOI:10.5500/wjt.v14.i3.92335

Georgia Andriana Georgopoulou, Marios Papasotiriou, Theodoros Ntrinias, Eirini Savvidaki, Dimitrios S Goumenos, Evangelos Papachristou

{"title":"Impact of bisphosphonate treatment on bone mineral density after kidney transplant.","authors":"Georgia Andriana Georgopoulou, Marios Papasotiriou, Theodoros Ntrinias, Eirini Savvidaki, Dimitrios S Goumenos, Evangelos Papachristou","doi":"10.5500/wjt.v14.i3.92335","DOIUrl":null,"url":null,"abstract":"Background: Mineral bone disease is associated with chronic kidney disease and persists after kidney transplantation. Immunosuppressive treatment contributes to the pathogenesis of this disease. Bisphosphonate treatments have shown positive but indefinite results.Aim: To evaluate the effectiveness and safety of bisphosphonate treatment on post kidney transplantation bone mineral density (BMD).Methods: We included kidney transplant recipients (KTRs) whose BMD was measured after the operation but before the initiation of treatment and their BMD was measured at least one year later. We also evaluated the BMD of KTRs using two valid measurements after transplantation who received no treatment (control group).Results: Out of 254 KTRs, 62 (39 men) were included in the study. Bisphosphonates were initiated in 35 KTRs in total (20 men), 1.1 ± 2.4 years after operation and for a period of 3.9 ± 2.3 years while 27 (19 men) received no treatment. BMD improved significantly in KTRs who received bisphosphonate treatments (from -2.29 ± 1.07 to -1.66 ± 1.09, P < 0.0001). The control group showed a non-significant decrease in BMD after 4.2 ± 1.4 years of follow-up after surgery. Kidney function was not affected by bisphosphonate treatment. In KTRs with established osteoporosis, active treatment had a similar and significant effect on those with osteopenia or normal bone mass.Conclusion: In this retrospective study of KTRs receiving bisphosphonate treatment, we showed that active treatment is effective in preventing bone loss irrespective of baseline BMD.","PeriodicalId":65557,"journal":{"name":"世界移植杂志","volume":"14 3","pages":"92335"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11317859/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"世界移植杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5500/wjt.v14.i3.92335","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Mineral bone disease is associated with chronic kidney disease and persists after kidney transplantation. Immunosuppressive treatment contributes to the pathogenesis of this disease. Bisphosphonate treatments have shown positive but indefinite results.

Aim: To evaluate the effectiveness and safety of bisphosphonate treatment on post kidney transplantation bone mineral density (BMD).

Methods: We included kidney transplant recipients (KTRs) whose BMD was measured after the operation but before the initiation of treatment and their BMD was measured at least one year later. We also evaluated the BMD of KTRs using two valid measurements after transplantation who received no treatment (control group).

Results: Out of 254 KTRs, 62 (39 men) were included in the study. Bisphosphonates were initiated in 35 KTRs in total (20 men), 1.1 ± 2.4 years after operation and for a period of 3.9 ± 2.3 years while 27 (19 men) received no treatment. BMD improved significantly in KTRs who received bisphosphonate treatments (from -2.29 ± 1.07 to -1.66 ± 1.09, P < 0.0001). The control group showed a non-significant decrease in BMD after 4.2 ± 1.4 years of follow-up after surgery. Kidney function was not affected by bisphosphonate treatment. In KTRs with established osteoporosis, active treatment had a similar and significant effect on those with osteopenia or normal bone mass.

Conclusion: In this retrospective study of KTRs receiving bisphosphonate treatment, we showed that active treatment is effective in preventing bone loss irrespective of baseline BMD.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

双膦酸盐治疗对肾移植后骨矿物质密度的影响。

背景：矿物质骨病与慢性肾脏病有关，并且在肾移植后仍然存在。免疫抑制治疗是该病的发病机制之一。目的：评估双膦酸盐治疗对肾移植后骨矿物质密度（BMD）的有效性和安全性：方法：我们纳入了肾移植受者（KTR），在手术后但开始治疗前测量了他们的骨密度，并在至少一年后测量了他们的骨密度。我们还评估了未接受治疗的 KTR 移植后两次有效测量的 BMD（对照组）：在 254 名 KTR 中，有 62 人（39 名男性）被纳入研究。共有 35 名 KTR（20 名男性）在手术后 1.1 ± 2.4 年和 3.9 ± 2.3 年期间开始服用双膦酸盐，27 名 KTR（19 名男性）未接受任何治疗。接受双膦酸盐治疗的 KTR 的 BMD 有明显改善（从 -2.29 ± 1.07 到 -1.66 ± 1.09，P < 0.0001）。对照组在术后随访 4.2 ± 1.4 年后，BMD 出现了不明显的下降。肾功能未受到双膦酸盐治疗的影响。在已确诊骨质疏松症的 KTR 患者中，积极治疗对骨质疏松或骨量正常的患者有类似的显著效果：在这项对接受双膦酸盐治疗的 KTR 进行的回顾性研究中，我们发现，无论基线 BMD 如何，积极治疗都能有效预防骨质流失。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

世界移植杂志

CiteScore

3.50

自引率

0.00%

发文量

293